Patents by Inventor Takahiro Oi
Takahiro Oi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11945333Abstract: A communication device includes a communicator that is mounted in a mobile body and functions as a wireless access point, a power supplier configured to supply electric power at least to a driver that causes the mobile body to travel, a detector configured to detect the electric energy of the power supplier, and a controller configured to control at least one of communication strength and communication quality of the communicator based on the electric energy detected by the detector.Type: GrantFiled: December 24, 2020Date of Patent: April 2, 2024Assignee: HONDA MOTOR CO., LTD.Inventors: Masaru Otaka, Ryusuke Tamanaha, Yusuke Oi, Takahiro Iijima, Naoko Imai
-
Patent number: 11935354Abstract: A communication device includes a communicator controller. The communication controller configured to cause a communicator to communicate with a terminal device in a first mode or a second mode, in which the first mode is a mode in which communication conditions are better than in the second mode, and, when the communication controller has acquired permission information indicating that communication in the first mode is permitted according to completion of processing of a first procedure different from a second procedure required for communication in the second mode in response to a request from the terminal device, the communication controller causes the communicator to communicate with a terminal device associated with the permission information in the first mode.Type: GrantFiled: December 29, 2020Date of Patent: March 19, 2024Assignee: HONDA MOTOR CO., LTD.Inventors: Masaru Otaka, Ryusuke Tamanaha, Yusuke Oi, Takahiro Iijima, Naoko Imai
-
Patent number: 9422240Abstract: There are provided compounds having a superior PHD2 inhibitory effect that are represented by general formula (I?): (in the above-mentioned general formula (I?), W, Y, R2, R3, R4, and Y4 are as described hereinabove), or pharmaceutically acceptable salts thereof.Type: GrantFiled: July 29, 2013Date of Patent: August 23, 2016Assignee: TAISHO PHARMACEUTICAL CO., LTDInventors: Tetsuo Takayama, Tsuyoshi Shibata, Fumiyasu Shiozawa, Kenichi Kawabe, Yuki Shimizu, Makoto Hamada, Akira Hiratate, Masato Takahashi, Fumihito Ushiyama, Takahiro Oi, Yoshihisa Shirasaki, Daisuke Matsuda, Chie Koizumi, Sota Kato
-
Patent number: 9161945Abstract: A compound, which inhibits SGLT1 (sodium-dependent glucose transporter 1) activity to suppress absorption of glucose or the like, thereby suppressing abnormal glucose tolerance or postprandial hyperglycemia in diabetes, is provided.Type: GrantFiled: August 19, 2011Date of Patent: October 20, 2015Assignee: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Hiroyuki Kakinuma, Yohei Kobashi, Tomomichi Chonan, Fumiyasu Shiozawa, Yuki Iwata, Takahiro Oi, Kenichi Kawabe
-
Publication number: 20150175541Abstract: There are provided compounds having a superior PHD2 inhibitory effect that are represented by general formula (I?): (in the above-mentioned general formula (I?), W, Y, R2, R3, R4, and Y4 are as described hereinabove), or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: July 29, 2013Publication date: June 25, 2015Applicant: TAISHO PHARMACEUTICAL CO., LTDInventors: Tetsuo Takayama, Tsuyoshi Shibata, Fumiyasu Shiozawa, Kenichi Kawabe, Yuki Shimizu, Makoto Hamada, Akira Hiratate, Masato Takahashi, Fumihito Ushiyama, Takahiro Oi, Yoshihisa Shirasaki, Daisuke Matsuda, Chie Koizumi, Sota Kato
-
Patent number: 9035059Abstract: There are provided compounds represented by the following general formula (I) or pharmaceutically acceptable salts of thereof, which have a superior monoacylglycerol acyltransferase 2 inhibitory action: wherein Ring A represents a partially saturated heteroaryl group, an aryl group or a heteroaryl group, RB represents a C4-18 alkyl group, a C3-8 cycloalkyl group, a partially saturated aryl group, an aryl group, or the following formula (II): wherein V represents the formula —CR11R12—, —CO—, —CO—O—, or —CO—NH—, W represents a single bond or a C1-3 alkylene group, and Ring B represents a C3-8 cycloalkyl group, a C3-8 cycloalkenyl group, a partially saturated heteroaryl group, a saturated heterocyclyl group, an aryl group, or a heteroaryl group, Y represents a nitrogen atom or the formula N+(RF), RF represents a C1-4 alkyl group, and m and n, which may be the same or different, each represent an integer of 0 or 1.Type: GrantFiled: March 14, 2012Date of Patent: May 19, 2015Assignee: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Tsuyoshi Busujima, Takahiro Oi, Hiroaki Tanaka, Yoshihisa Shirasaki, Kanako Iwakiri, Nagaaki Sato, Shigeru Tokita
-
Patent number: 8637557Abstract: A compound represented by formula (1) or a pharmaceutically acceptable salt thereof, which has a PI3 kinase ? inhibitory effect and is useful as a prophylactic or therapeutic agent for articular rheumatism, Crohn's disease, irritable colitis, Sjoegren's syndrome, multiple sclerosis, systemic lupus erythematosus, asthma, atopic dermatitis, arteriosclerosis, organ transplant rejection, cancer, retinopathy, psoriasis, arthrosis deformans, age-related macular degeneration, type II diabetes, insulin resistance, obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), hyperlipemia, etc.Type: GrantFiled: October 4, 2010Date of Patent: January 28, 2014Assignee: Taisho Pharmaceutical Co., LtdInventors: Tetsuya Yabuuchi, Yusuke Oka, Shoichi Kuroda, Takahiro Oi, Yoshinori Sekiguchi
-
Publication number: 20140005382Abstract: There are provided compounds represented by the following general formula (I) or pharmaceutically acceptable salts of thereof, which have a superior monoacylglycerol acyltransferase 2 inhibitory action: wherein Ring A represents a partially saturated heteroaryl group, an aryl group or a heteroaryl group, RB represents a C4-18 alkyl group, a C3-8 cycloalkyl group, a partially saturated aryl group, an aryl group, or the following formula (II): wherein V represents the formula —CR11R12—, —CO—, —CO—O—, or —CO—NH—, W represents a single bond or a C1-3 alkylene group, and Ring B represents a C3-8 cycloalkyl group, a C3-8 cycloalkenyl group, a partially saturated heteroaryl group, a saturated heterocyclyl group, an aryl group, or a heteroaryl group, Y represents a nitrogen atom or the formula N+(RF), RF represents a C1-4 alkyl group, and m and n, which may be the same or different, each represent an integer of 0 or 1.Type: ApplicationFiled: March 14, 2012Publication date: January 2, 2014Applicant: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Tsuyoshi Busujima, Takahiro Oi, Hiroaki Tanaka, Yoshihisa Shirasaki, Kanako Iwakiri, Nagaaki Sato, Shigeru Tokita
-
Publication number: 20130165645Abstract: A compound, which inhibits SGLT1 (sodium-dependent glucose transporter 1) activity to suppress absorption of glucose or the like, thereby suppressing abnormal glucose tolerance or postprandial hyperglycemia in diabetes, is provided.Type: ApplicationFiled: August 19, 2011Publication date: June 27, 2013Applicant: TAISHO PHARMACEUTICAL CO., LTDInventors: Hiroyuki Kakinuma, Yohei Kobashi, Tomomichi Chonan, Fumiyasu Shiozawa, Yuki Iwata, Takahiro Oi, Kenichi Kawabe
-
Patent number: 8466113Abstract: The present invention provides 4-isopropylphenyl glucitol compounds which have no tendency to accumulate in the body and which inhibit SGLT1 activity to suppress postprandial hyperglycemia (or impaired glucose tolerance) through suppression of glucose absorption in the small intestine, whereby the compounds, for example, can suppress the onset of diabetes and metabolic syndrome or can treat these diseases. A 4-isopropylphenyl glucitol compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: wherein R1 represents a hydrogen atom, etc., R2 represents a methyl group, etc., R3 represents a C1-4 alkyl group substituted with an amino group(s), etc., and R4 represents a hydrogen atom, etc.Type: GrantFiled: February 23, 2010Date of Patent: June 18, 2013Assignee: Taisho Pharmaceutical Co., Ltd.Inventors: Hiroyuki Kakinuma, Yohei Kobashi, Tomomichi Chonan, Takahiro Oi, Fumiyasu Shiozawa, Yuki Iwata, Kenichi Kawabe
-
Patent number: 8461329Abstract: A compound represented by formula (I) or a pharmaceutically acceptable salt thereof has an effect of inhibiting CRTH2 and, therefore, is useful as a preventive or a remedy for allergic diseases such as asthma, atopic dermatitis and allergic rhinitis.Type: GrantFiled: December 25, 2009Date of Patent: June 11, 2013Assignee: Taisho Pharmaceutical Co., Ltd.Inventors: Tetsuo Takayama, Hajime Asanuma, Daisuke Wakasugi, Rie Nishikawa, Yoshinori Sekiguchi, Madoka Kawamura, Naoya Ono, Tetsuya Yabuuchi, Takahiro Oi, Yusuke Oka, Shoichi Kuroda, Fumito Uneuchi, Takeshi Koami
-
Publication number: 20120220767Abstract: A compound represented by formula (1) or a pharmaceutically acceptable salt thereof, which has a PI3 kinase ? inhibitory effect and is useful as a prophylactic or therapeutic agent for articular rheumatism, Crohn's disease, irritable colitis, Sjoegren's syndrome, multiple sclerosis, systemic lupus erythematosus, asthma, atopic dermatitis, arteriosclerosis, organ transplant rejection, cancer, retinopathy, psoriasis, arthrosis deformans, age-related macular degeneration, type II diabetes, insulin resistance, obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), hyperlipemia, etc.Type: ApplicationFiled: October 4, 2010Publication date: August 30, 2012Applicant: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Tetsuya Yabuuchi, Yusuke Oka, Shoichi Kuroda, Takahiro Oi, Yoshinori Sekiguchi
-
Patent number: 8115017Abstract: C-phenyl 1-thioglucitol compounds of the following formula (I) or pharmaceutically acceptable salts thereof or hydrates thereof: [wherein X represents a hydrogen atom or a C1-6 alkyl group, Y represents a C1-6 alkylene group or —O—(CH2)n- (wherein n represents an integer of 1 to 5), and Z represents —CONHRA or —NHCONHRB (provided that when Z represents —NHCONHRB, n is not 1), wherein RA represents a C1-6 alkyl group substituted with 1 to 3 substituents selected from the group consisting of a hydroxyl group and —CONH2, and RB represents a hydrogen atom or a C1-6 alkyl group substituted with 1 to 3 substituents selected from the group consisting of a hydroxyl group and —CONH2] are useful as prophylactic or therapeutic agents for diabetes, because of their suppressive effect on sugar (e.g., glucose) absorption through inhibition of SGLT1 activity, or alternatively, because of their suppressive effect on sugar (e.g.Type: GrantFiled: June 28, 2007Date of Patent: February 14, 2012Assignee: Taisho Pharmaceutical Co., LtdInventors: Hiroyuki Kakinuma, Takahiro Oi, Yohei Kobashi, Yuko Hashimoto, Hitomi Takahashi
-
Publication number: 20110306759Abstract: The present invention provides 4-isopropylphenyl glucitol compounds which have no tendency to accumulate in the body and which inhibit SGLT1 activity to suppress postprandial hyperglycemia (or impaired glucose tolerance) through suppression of glucose absorption in the small intestine, whereby the compounds, for example, can suppress the onset of diabetes and metabolic syndrome or can treat these diseases. A 4-isopropylphenyl glucitol compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: wherein R1 represents a hydrogen atom, etc., R2 represents a methyl group, etc., R3 represents a C1-4 alkyl group substituted with an amino group(s), etc., and R4 represents a hydrogen atom, etc.Type: ApplicationFiled: February 23, 2010Publication date: December 15, 2011Applicant: TAISHO PHARMACEUTICAL CO., LTDInventors: Hiroyuki Kakinuma, Yohei Kobashi, Tomomichi Chonan, Takahiro Oi, Fumiyasu Shiozawa, Yuki Iwata, Kenichi Kawabe
-
Publication number: 20110288293Abstract: A compound represented by formula (I) or a pharmaceutically acceptable salt thereof has an effect of inhibiting CRTH2 and, therefore, is useful as a preventive or a remedy for allergic diseases such as asthma, atopic dermatitis and allergic rhinitis.Type: ApplicationFiled: December 25, 2009Publication date: November 24, 2011Applicant: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Tetsuo Takayama, Hajime Asanuma, Daisuke Wakasugi, Rie Nishikawa, Yoshinori Sekiguchi, Madoka Kawamura, Naoya Ono, Tetsuya Yabuuchi, Takahiro Oi, Yusuke Oka, Shoichi Kuroda, Fumito Uneuchi, Takeshi Koami
-
Patent number: 7973012Abstract: Provided is a novel C-phenyl glycitol compound that may serve as a prophylactic or therapeutic agent for diabetes by inhibiting both SGLT1 activity and SGLT2 activity, thereby exhibiting a glucose absorption suppression action and a urine glucose excretion action.Type: GrantFiled: May 18, 2007Date of Patent: July 5, 2011Assignee: Taisho Pharmaceutical Co., LtdInventors: Hiroyuki Kakinuma, Yohei Kobashi, Yuko Hashimoto, Takahiro Oi, Hitomi Takahashi, Hideaki Amada, Yuki Iwata
-
Patent number: 7910619Abstract: The present invention provides a 1-thio-D-glucitol compound of the following formula, which shows the action of inhibiting the activity of SGLT2, a pharmaceutically acceptable salt of the compound, or a hydrate of the compound or the salt; and a pharmaceutical comprising such a compound as an active ingredient, especially, a pharmaceutical for preventing or treating diabetes, diabetes-related disease, or diabetic complication. The invention also provides a method for producing the 1-thio-D-glucitol compound and its intermediate.Type: GrantFiled: January 10, 2006Date of Patent: March 22, 2011Assignee: Taisho Pharmaceutical Co., Ltd.Inventors: Hiroyuki Kakinuma, Yuko Hashimoto, Takahiro Oi, Hitomi Takahashi
-
Publication number: 20100069460Abstract: A 1-phenyl 1-thio-D-glucitol compound represented by formula (I) or the like: or a pharmaceutically acceptable salt thereof or a hydrate thereof, or a pharmaceutical preparation comprising the same as an active ingredient is useful as a novel type of prophylactic or therapeutic agent for diabetes, diabetes-related diseases or diabetic complications, which inhibits both SGLT1 and SGLT2 activities to achieve not only suppression of glucose absorption from the digestive tract but also excretion of urinary sugars.Type: ApplicationFiled: December 14, 2007Publication date: March 18, 2010Applicant: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Hiroyuki Kakinuma, Takahiro Oi, Yuko Hashimoto, Hitomi Takahashi, Yohei Kobashi, Yuki Iwata, Kenichi Kawabe, Masato Takahashi
-
Publication number: 20100022460Abstract: Provided is a novel C-phenyl glycitol compound that may serve as a prophylactic or therapeutic agent for diabetes by inhibiting both SGLT1 activity and SGLT2 activity, thereby exhibiting a glucose absorption suppression action and a urine glucose excretion action.Type: ApplicationFiled: May 18, 2007Publication date: January 28, 2010Applicant: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Hiroyuki Kakinuma, Yohei Kobashi, Yuko Hashimoto, Takahiro Oi, Hitomi Takahashi, Hideaki Amada, Yuki Iwata
-
Publication number: 20100004465Abstract: C-phenyl 1-thioglucitol compounds of the following formula (I) or pharmaceutically acceptable salts thereof or hydrates thereof: [wherein X represents a hydrogen atom or a C1-6 alkyl group, Y represents a C1-6 alkylene group or —O—(CH2)n- (wherein n represents an integer of 1 to 5), and Z represents —CONHRA or —NHCONHRB (provided that when Z represents —NHCONHRB, n is not 1), wherein RA represents a C1-6 alkyl group substituted with 1 to 3 substituents selected from the group consisting of a hydroxyl group and —CONH2, and RB represents a hydrogen atom or a C1-6 alkyl group substituted with 1 to 3 substituents selected from the group consisting of a hydroxyl group and —CONH2] are useful as prophylactic or therapeutic agents for diabetes, because of their suppressive effect on sugar (e.g., glucose) absorption through inhibition of SGLT1 activity, or alternatively, because of their suppressive effect on sugar (e.g.Type: ApplicationFiled: June 28, 2007Publication date: January 7, 2010Applicant: Taisho Pharmaceutical Co., LtdInventors: Hiroyuki Kakinuma, Takahiro Oi, Yohei Kobashi, Yuko Hashimoto, Hitomi Takahashi